XNCR: Xencor, Inc. Stock

by  •  • Comments Off on XNCR: Xencor, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 947.71
Enterprise Value ($M) 1,066.86
Book Value ($M) 674.03
Book Value / Share 9.57
Price / Book 1.41
NCAV ($M) 299.68
NCAV / Share 4.25
Price / NCAV 3.16

Profitability (mra)
Return on Invested Capital (ROIC) -0.26
Return on Assets (ROA) -0.24
Return on Equity (ROE) -0.35

Liquidity (mrq)
Quick Ratio 6.61
Current Ratio 6.61

Balance Sheet (mrq) ($M)
Current Assets 577.60
Assets 951.95
Liabilities 277.92
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 110.49
Operating Income -176.08
Net Income -232.62
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -202.19
Cash from Investing -7.87
Cash from Financing 197.15

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-05 13G/A BlackRock, Inc. 17.40 10.66
11-14 13G/A EcoR1 Capital, LLC 9.40 27.20
11-14 13G/A Price T Rowe Associates Inc /md/ 5.60 12.58
11-12 13G/A Primecap Management Co/ca/ 13.08 2.65
10-18 13G/A State Street Corp 4.50 -6.24
2024-02-16 13G/A T. Rowe Price Investment Management, Inc. 2.20 0.00
2024-02-13 13G/A Vanguard Group Inc 11.12 1.73

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT
2025-02-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2025-02-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2025-02-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2025-02-24 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSI
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-12 118,777 552,049 21.52
2025-03-11 126,008 501,623 25.12
2025-03-10 115,195 568,403 20.27
2025-03-07 73,866 336,139 21.97

(click for more detail)

Similar Companies
VRCA – Verrica Pharmaceuticals Inc. WVE – Wave Life Sciences Ltd.
XENE – Xenon Pharmaceuticals Inc. XOMA – XOMA Royalty Corporation


Financial data and stock pages provided by
Fintel.io